Latest news with #FujifilmHoldingsCorp
Yahoo
07-08-2025
- Business
- Yahoo
FUJIFILM's Q1 Earnings Decline Y/Y, Imaging Solutions Boost Revenues
FUJIFILM Holdings Corporation FUJIY reported a first-quarter fiscal 2025 (ended June 30, 2025) net income of ¥53.8 billion compared with ¥60.7 billion in the year-ago quarter. The decrease was primarily as a result of foreign exchange losses. Revenues of ¥749.5 billion inched up 0.1% year over year. The stable performance was primarily driven by strong performances in Bio CDMO, Semiconductor Materials and Imaging segments, offsetting the impact of foreign exchange fluctuations. Segment Details of FUJIY In June 2024, the company established the Advanced Functional Materials division by integrating its display materials, industrial products and fine chemicals businesses. In the fiscal first quarter, Healthcare segment revenues were ¥228.5 billion, down 2.9% from the year-ago quarter. Within Healthcare, Medical Systems revenues were down 8.7% year over year to ¥144 billion. Revenues decreased primarily due to lower demand for medical consumables in China and the absence of large-scale orders for X-ray imaging diagnostic equipment, which had contributed significantly in the previous year. However, this decline was partially offset by strong sales of medical IT solutions such as PACS, along with solid performance in in-vitro diagnostics (IVD) and endoscopes. Bio CDMO revenues were up 12.8% to ¥53.2 billion. Revenues grew primarily due to the commencement of operations at the new Danish facilities and the resumption of operations at the Texas facilities. This growth was partially offset by the impact of regularly scheduled maintenance at the existing Danish sciences revenues grew 3.2% to ¥31.3 billion, driven by a recovery in the culture media market and robust sales of reagents. Fujifilm Holdings Corp. Price, Consensus and EPS Surprise Fujifilm Holdings Corp. price-consensus-eps-surprise-chart | Fujifilm Holdings Corp. Quote In the Electronics segment, revenues amounted to ¥102.1 billion, down 0.9% year over year. Semiconductor Materials revenues rose 3.8% to ¥64.7 billion. Revenues grew on the back of strong sales in advanced applications, particularly in CMP slurry. AF materials revenues amounted to ¥37.5 billion, down 8.2% year over year. This was due to a decline in data tape sales following significant purchases by IT companies in the previous year, while strong sales of new materials boosted the performance of display materials. The Business Innovation Solutions segment's revenues were ¥273.6 billion, decreasing 2.3% from the year-ago quarter's figure. Business solutions moved up 7% on a year-over-year basis to ¥75.8 billion. Revenues were supported by strong sales of digital transformation (DX) solutions and services to municipalities in Japan, along with increased business process outsourcing (BPO) revenue from markets outside Japan. Office solutions and Graphic Communications revenues decreased 5.3% and 5.6% on a year-over-year basis to ¥120 billion and ¥77.8 billion, respectively. In the Office Solutions segment, revenues were adversely impacted by a strategic reduction in the range of low-profit products sold in China. Within Graphic Communications, analog printing faced weaker demand for plate-making and the discontinuation of low-margin products, while inkjet printhead sales declined due to reduced demand from the ceramics market. The Imaging Solutions segment's revenues were ¥145.3 billion, up 11.2% from the year-ago quarter's level. Consumer Imaging and Professional Imaging revenues rose 3.7% and 21.2% on a year-over-year basis to ¥77.3 billion and ¥68 billion, respectively. In the Consumer Imaging segment, strong sales of Instax instant photo systems drove growth, supported by the popularity of models such as the Instax WIDE 400 and Instax WIDE Evo, along with contributions from the newly launched Instax mini 41. In the Professional Imaging segment, robust sales of FUJIFILM X and GFX series digital cameras contributed to strong performance, with particularly high demand for the FUJIFILM X100VI and X-M5 models, as well as positive contributions from the newly introduced FUJIFILM GFX100RF and X half. FUJIY's Operating Details In the fiscal first quarter, selling, general and administrative expenses decreased 4.6% to ¥196.6 billion. Research and development expenses increased 0.9% to ¥40.6 billion. Operating income increased 21.1% year over year to ¥75.3 billion, primarily due to higher sales in the Imaging segment, while the effect of U.S. tariff policies remained minimal. FUJIY's Balance Sheet & Cash Flow As of June 30, 2025, cash and cash equivalents were ¥160 billion, down from ¥172.1 billion as of March 31, 2025. Total debt was ¥749.8 billion as of March 31, 2025, compared with ¥685.9 billion on as of March 31, 2025. For full-year 2025, FUJIFILM is planning an annual dividend of ¥70 per share, marking the 16th consecutive year of dividend increases. FUJIY's Guidance FUJIFILM reiterated its guidance for fiscal 2025. The company expects revenues of ¥3,280 billion for fiscal 2025, indicating growth of 2.6% year over year. The operating income is anticipated to be ¥331 billion, implying 0.3% growth. Net income is expected to increase 0.4% year over year to ¥262 billion. For fiscal 2025, revenues from Healthcare, Electronics, Business Innovation and Imaging Solutions are anticipated to be ¥1,110 billion, ¥420 billion, ¥1,220 billion and ¥540 billion, respectively. Zacks Rank of FUJIY Currently, FUJIFILM has a Zacks Rank #3 (Hold). In the past six months, shares have soared 8.8% compared with the Zacks Semiconductor Equipment – Photomasks industry's decline of 13.4%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Image Source: Zacks Investment Research Recent Performance of Other Companies in Tech Space Blackbaud, Inc. BLKB reported second-quarter 2025 non-GAAP earnings per share (EPS) of $1.21, which surpassed the Zacks Consensus Estimate by 15.2%. The bottom line increased around 12% year over year. Total revenues decreased 2.1% year over year to $281.4 million. This was due to the divestiture of EVERFI. The top line surpassed the Zacks Consensus Estimate by 1.3%. In the past year, shares of BLKB have lost 17.5%. Fortive Corporation FTV reported second-quarter 2025 adjusted EPS of 58 cents from continuing operations, which missed the Zacks Consensus Estimate of 60 cents. The bottom line increased 3.6% year over year. Revenues declined 0.4% year over year to $1.02 billion. The top line beat the Zacks Consensus Estimate by 0.8%. Core revenues decreased 0.7% year over year. In the past, shares of FTV have declined 27.7% Flex Ltd. FLEX reported first-quarter fiscal 2026 adjusted EPS of 72 cents, which surpassed the Zacks Consensus Estimate by 14.3%. The bottom line compared favorably with 51 cents posted in the prior-year quarter. Revenues increased 4.1% year over year to $6.6 billion. Also, it beat the consensus mark by 5.6%. The uptick was driven by strong data center growth in both the cloud and power end markets. Shares of FLEX have surged 79.9% in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fujifilm Holdings Corp. (FUJIY) : Free Stock Analysis Report Flex Ltd. (FLEX) : Free Stock Analysis Report Blackbaud, Inc. (BLKB) : Free Stock Analysis Report Fortive Corporation (FTV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
07-08-2025
- Business
- Yahoo
Why Fujifilm Holdings Corp. (FUJIY) is a Top Value Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Why Investors Should Pay Attention to This Value Stock Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks. Fujifilm Holdings Corp. (FUJIY) Tokyo-based FUJIFILM Holdings Corporation leverages its expertise in photographic film technology to target opportunities in the Healthcare, Electronics and Imaging markets has a diversified business ranging from imaging (photoimaging, optics) to healthcare and materials (high-performance materials, graphic systems/inkjet, recording media). The company reported revenues of ¥2,960.9 billion, up 3.6% year over year in fiscal 2023. After the reorganization of its operating segments during the current year, FUJIFILM reports results under four divisions - Healthcare, Electronics, Business Innovation and Imaging. FUJIY is a Zacks Rank #3 (Hold) stock, with a Value Style Score of B and VGM Score of B. Shares are currently trading at a forward P/E of 15.2X for the current fiscal year compared to the Semiconductor Equipment - Photomasks industry's P/E 13.2X. Additionally, FUJIY has a PEG Ratio of 3.3 and a Price/Cash Flow ratio of 9.8X. Value investors should also note FUJIY's Price/Sales ratio of 1.3X. A company's earnings performance is important for value investors as well. For fiscal 2026, two analysts revised their earnings estimate higher in the last 60 days for FUJIY, while the Zacks Consensus Estimate has increased $0.02 to $0.73 per share. FUJIY also holds an average earnings surprise of 5.7%. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding FUJIY to their portfolios. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fujifilm Holdings Corp. (FUJIY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Star
04-08-2025
- Business
- The Star
Fujifilm raises camera and lens prices in the US amid tariffs
Camera bodies, which are popular with creators and professionals on account of their film simulations and unique color rendering, are now US$200 (RM847) more expensive than they were on last Thursday evening. — Pixabay Fujifilm Holdings Corp raised US prices for the majority of its digital cameras and lenses last Friday, in some cases by hundreds of dollars, as President Donald Trump's tariffs continue to reverberate across the consumer tech industry. Many of the company's camera bodies, which are popular with creators and professionals on account of their film simulations and unique color rendering, are now US$200 (RM847) more expensive than they were on last Thursday evening. For instance, Fujifilm's premier consumer camera, the X-T5, sold for US$1,699 (RM 7,196) earlier but now costs US$1,899 (RM 8,043) , a 12% bump. Fujifilm did not respond to an emailed request for comment. The company is headquartered in Japan, which is subject to a baseline 15% tariff under a deal that the Trump administration struck with the country last month. Fujifilm subsequently relocated manufacturing for a few camera models from China to Japan; during that time, the prices remained stable. Other consumer hardware makers have also raised prices in recent months, including Kyoto-based Nintendo Co, which earlier announced a US price increase for the original Switch handheld games console, citing "market conditions.' Fujifilm is the fourth-largest camera maker behind Canon Inc, Sony Group Corp and Nikon Corp, according to market research firm Techno Systems Research. But the brand's products often stir an outsized buzz on social media among tech enthusiasts. Its X100 series went viral on TikTok during the Covid pandemic and has consistently been on backorder at most retailers since then. The latest model in that lineup, the X100VI, has risen to US$1,799 (RM7,620) with the latest price changes – up from US$1,599 (RM6,772). As for the other major camera manufacturers, Canon, Sony and Nikon already raised prices for a number of products earlier this year. Smaller players like Sigma have also given in after months of global tariff anxiety; that brand increased the cost of its lenses by around 10% in June, the photography outlet PetaPixel reported at the time, but the company told retail partners it's not planning another hike despite the new 15% rate levied on Japan. Fujifilm's most recently announced mirrorless camera, the X-E5 unveiled in June, has not undergone any price adjustments. That product is scheduled to ship later in August. The X Half, a compact, lightweight model the company introduced this year to attract more Gen Z customers, has also maintained its US$850 (RM3,600) price for the time being. – Bloomberg
Yahoo
30-07-2025
- Business
- Yahoo
Fujifilm Holdings Corp. (FUJIY) is a Top-Ranked Growth Stock: Should You Buy?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Why This 1 Growth Stock Should Be On Your Watchlist Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time. Fujifilm Holdings Corp. (FUJIY) Tokyo-based FUJIFILM Holdings Corporation leverages its expertise in photographic film technology to target opportunities in the Healthcare, Electronics and Imaging markets has a diversified business ranging from imaging (photoimaging, optics) to healthcare and materials (high-performance materials, graphic systems/inkjet, recording media). The company reported revenues of ¥2,960.9 billion, up 3.6% year over year in fiscal 2023. After the reorganization of its operating segments during the current year, FUJIFILM reports results under four divisions - Healthcare, Electronics, Business Innovation and Imaging. FUJIY is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of B and VGM Score of B. Earnings are expected to grow 2.8% year-over-year for the current fiscal year, with sales growth of 8.3%. Two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.02 to $0.73 per share for 2026. FUJIY boasts an average earnings surprise of 8.6%. Fujifilm Holdings Corp. is also cash rich. The company has generated cash flow growth of 4.2%, and is expected to report cash flow expansion of 2.6% in 2026. Investors should take the time to consider FUJIY for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fujifilm Holdings Corp. (FUJIY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yomiuri Shimbun
27-04-2025
- Business
- Yomiuri Shimbun
Global Pharma Companies Rush to Invest in U.S., as Trump Administration Examines Tariff on Drug Imports
Courtesy of Fujifilm Holdings Corp. Fujifilm's pharmaceutical plant in North Carolina is currently under construction. Pharmaceutical companies around the world, including those in Japan, are expanding investment in the United States. While the country is the world's largest market for pharmaceuticals, accounting for more than 40% of global sales, U.S. President Donald Trump could soon impose new tariffs on drug imports. Pharma companies are trying to move quickly to minimize the impact of tariffs by adding more production sites in the United States. On April 22, Fujifilm Holdings Corp. announced that it had signed a manufacturing and supply agreement with major U.S. pharma company Regeneron Pharmaceuticals, Inc. Under the contract, Regeneron will receive biopharmaceuticals produced in the United States. The deal is worth $3 billion (about ¥430 billion), which is reportedly one of the largest manufacturing and supply agreements made public in the United States. The drugs will be produced at Fujifilm's new manufacturing facility in North Carolina, which will begin operations later this year. Fujifilm entered the biopharmaceutical development and contract manufacturing business in 2011. The company has invested about $4 billion (about ¥570 billion) in facilities and equipment in the United States, and its manufacturing facility in North Carolina will be the company's fifth production site in the United States. Fujifilm aims to increase its biopharma sales to ¥700 billion by fiscal 2030, more than three times current sales. While Trump's reciprocal tariffs do not affect pharmaceuticals, his administration has already begun investigating drug imports, looking to possibly impose duties on them as well. 'This would affect exports from Japan to the United States, which could lead to a decline in revenue for pharmaceutical companies,' said Hiroaki Ueno, president of the Japan Pharmaceutical Manufacturers Association and representative director of Mitsubishi Tanabe Pharma Corp. Western firms also hurrying A growing number of U.S. and European pharmaceutical companies have also been announcing plans to increase investment in the United States. F. Hoffmann-La Roche Ltd., a major pharmaceutical company based in Switzerland, said earlier this month it will invest $50 billion (about ¥7.2 trillion) in the United States over the next five years. In that same time span, Novartis AG will invest $23 billion (about ¥3.3 trillion) to build research and production facilities in the country. Eli Lilly and Co., a major U.S. pharmaceutical company, will build a new manufacturing facility in the United States. Chief Executive Officer David Ricks said that this would help increase exports of domestically produced pharmaceuticals to overseas markets and benefit the United States. Since the U.S. drug market is expected to grow, other pharmaceutical companies may also consider boosting investment in the United States. However, some firms are less eager to review their production systems due to the large amount of time and effort involved. 'Pharmaceuticals is not the kind of business where you can easily change your manufacturing sites,' said Naoki Okamura, president of Astellas Pharma Inc., at a press conference on Friday. 'Changing the current supply chain is not a practical solution.'
